Mesothelioma is an incurable cancer of the pleura with a life expectancy of less than 1 year. On the basis of in vivo efficacy seen with the herpes simplex virus type 1 thymidine kinase (HSVtk) suicide gene-modified PA1STK cell line and ganciclovir (GCV) in a murine model of mesothelioma, a first in humans, clinical trial was designed for this therapeutic concept. The study was a phase I clinical trial using direct infusion of escalating doses of HSVtk suicide gene-modified PA1STK cells directly into tumor-associated pleural effusions followed by 7 days of intravenous GCV infusion. Therapeutic levels of GCV in both serum and pleura were achieved within 1 h, and GCV trough levels remained above the therapeutic threshold for the duration of GCV treatment. The treatment was well tolerated without any Grade 3 or 4 toxicity observed. Significant inductions of both Th1 and Th2 cytokines up to 20-fold over baseline were observed. No significant differences were seen between serum and pleura cytokine profiles, with the exception of interleukin-10, which was consistently elevated in the pleura specimens. No objective radiographic responses were observed. The data indicate significant immunological responses and validate the principal anti-tumor mechanisms observed in preclinical models of mesothelioma in a human clinical trial.
Introduction
Although the concept of cancer immunotherapy has been pursued for many decades, only very recently results from two large randomized clinical studies conclusively demonstrated a statistically significant overall survival benefit. 1, 2 Many cancer gene therapies are in fact immunotherapies, that use gene transfer technologies to manipulate host anti-tumor responses. An example of the immunotherapy is the suicide gene therapy that utilizes the herpes simplex virus type 1 thymidine kinase (HSVtk) gene to treat cancer. This approach was one of the first gene therapeutic strategies developed. 3 Success of this concept depends on two key conditions, that is, the ability of actually delivering the therapeutic gene directly into the tumor, as well as achieving therapeutic levels of the prodrug ganciclovir (GCV) within the tumor environment.
GCV is a synthetic analog of 2 0 -deoxyguanosine, which was developed as an anti-viral agent for treating cytomegalovirus-associated infections. 4 The drug competitively inhibits HSVtk and at the same time is a poor substrate for cellular thymidine kinase. Viral HSVtk phosphorylates GCV into a cytotoxic product GCV-triphosphate. 5 Tumor cells transfected with HSVtk are killed after GCV incubation because of the intracellular conversion of GCV to GCV-triphosphate. However, even untransfected tumor cells located within the vicinity of HSVtktransduced cells are also killed. This phenomenon is known as the 'bystander effect.' In vitro, this effect is the result of GCV-triphosphate reaching adjacent cells via gap junctions. 6 In vivo, the bystander effect is further enhanced through immune-mediated induction of antitumor immunity. Experimental studies demonstrated this effect to be only present in vivo in immunocompetent animals, but not in immunodeficient mice. [7] [8] [9] [10] [11] [12] It is believed that HSVtk suicide gene therapy converts an immunoinhibitory environment into an immunostimulatory microenvironment. 13 The use of viral vectors is complex and costly. A much simplified, yet equally effective delivery system was developed that utilized instead of virus-based vectors, a genetically stably modified cell line encoding the HSVtk gene. The ideal tumor for this treatment strategy would be localized rather than a diffused systemic cancer. Malignant mesothelioma is a rare form of lung cancer originating from the pleura, which remains compartmentalized for most of the disease course. It is an occupational disease and is related to previous asbestos exposure. It presents initially with a pleural effusion and typically advances rapidly disseminating locally rather than systemically. Although some chemotherapies have shown a very modest survival benefit, the disease is considered incurable even at early stages and remains refractory to most standard forms of therapy.
14 Thus, mesothelioma presents an ideal platform for developing novel targeted therapies to regionally limited malignancies. Life expectancy remains approximately 9 months from the time of initial diagnosis, and chemoresponsive patients may only gain a few months. 14 The disease has also shown to be responsive to immune modulations and previous small clinical trials using immune-mediated intracavitary infusion of immune-stimulating cytokines demonstrating promising results, thus providing proof of concept for this strategy. [15] [16] [17] Previously, clinical trials were conducted using intrapleural injection of adenovirus encoding HSVtk, followed by systemic GCV infusion. 18, 19 In preclinical studies, we demonstrated that PA1STK cells were able to form gap junctions with human and murine mesothelioma cell lines and mediated tumor killing in a dose-dependent manner, both in vitro and in vivo. 9 On the basis of these data, we designed a phase I dose escalation trial in which patients with malignant mesothelioma were treated with intrapleural infusion of the gene-modified PA1STK cells, followed by 1 week of intravenously infused GCV. 20 An indwelling catheter placed over the site of the malignant pleural effusion permitted the monitoring of pharmacokinetics as well as intracavitary immune responses over time.
Patients and methods

Patients
The trial was approved by the LSU Institutional Review Board and the NIH Recombinant Advisory Committee. Patients had to be histologically diagnosed with malignant mesothelioma of the pleura. Eligible patients were also required to have a tumor-associated, accessible pleural effusion. The Eastern Cooperative Oncology Group (ECOG) performance status had to be 0-2. Normal liver and renal function, as well as normal hematological parameters were required, other significant comorbidites that could potentially be interfering with the study were excluded at the discretion of the principal investigator. A history of other malignancies was an exclusion criterion. Patients had to be treatment-naı¨ve. Baseline computer tomography of the chest and abdomen was obtained within 2 weeks before the study entry and was repeated every 3 months following completion of the study. Patients were recruited between 1997 and 1999.
Staging was performed using the TNM staging system. Patients had an indwelling catheter placed directly into the pleural effusion by a thoracic surgeon. A single dose of PA1STK cells was infused into the chest cavity of patients at a schedule and doses outlined in Table 1 . Cohorts 2-5 received a total of three infusions administered in 4-week intervals with intrapatient dose escalations as seen in Table 1 .
The cells were diluted in 500 cc of 0.9% saline and infused directly into the pleural cavity. The patients were hospitalized and received GCV 5 mg kg À1 every 12 h Â 14 doses via intravenous infusion.
Response assessment was made using the World Health Organization classification; toxicity assessments were made by the NCI-CTC version 1.0. Patient characteristics are described in Table 2 .
Culture and preparation of the PA1STK cell line
The human ovarian carcinoma cell line PA1STK, which was stably transduced with the HSVtk gene, has been previously described.
7 PA1STK seed cells were stored in a certified master cell bank (kindly provided by Dr Scott Freeman, Tulane University, New Orleans, USA). Before the commencement of the scheduled treatment, for each patient, a seed lot of cells was thawed, counted and checked for viability.
Cells were then cultured in AIM V (Gibco-Brl, Grand Island, NY, USA) media supplemented with 10% fetal calf serum. All reagents utilized were from one particular lot and were certified to be pathogen-free according to the good manufacturing practice requirements. Cells were maintained in an exponential growth phase in a humidified incubator at 37 1C in an atmosphere of 5% CO 2 and 95% air. The PA1STK monoclonal cell line contained a stably expressing HSVtk construct under the control of the Moloney virus 5 0 -long terminal repeat. These cells were grown until they had reached 80-90% confluency. At that time the cells were collected and irradiated with 10 000 rads in a Kobalt 60 irradiator (Nordion, Ottawa, Ontario, Canada). Cells were resuspended in phosphatebuffered saline, pH 7.4, solution. Sterility testing was performed for mycoplasma, by Gram staining and Limulus amoebae lysate test for endotoxin, before infusion into the patient.
Sample handling and GCV analysis Serum and pleural fluid samples for peak and trough levels were performed as indicated in the tables and Treatment of mesothelioma with gene-modified cells P Schwarzenberger et al obtained at the same time from the pleural indwelling catheter and the contralateral extremity of the GCV infusion. To determine the level of blood, besides pleural fluid and pleural fluid cell fraction, GCV concentrations during the initial phases of the treatment, additional specimens were obtained at T ¼ 0 h, T ¼ 0.7 h and T ¼ 1, 2, 3, 4 and 6 h. For the T ¼ 0 time point or the pre-dosing draw, blood and pleural fluid were drawn before the patients received their initial dose of GCV. Samples were immediately placed on ice and processed immediately. Blood samples were allowed to clot on ice and the serum was collected by centrifugation 3000 g for 5 min then stored at À80 1C. The pleural fluid samples were centrifuged at 500 g at 4 1C for 5 min. A 0.3 ml aliquot was added to 0.3 ml ice-cold H 2 O and vortexed for 5 s before adding 0.3 ml ice-cold 0.4 N perchloric acid and was vortexed further and a 5 min incubation step on ice was carried out and 0.125 ml of 10 N KOH was added. Samples were then stored at À80 1C until further analysis. The pleural fluid cell pellets were dissolved in 0.5 ml ice-cold H 2 O before the addition of 0.5 ml ice-cold 0.4 N perchloric acid, vortexed and followed by a 5-min incubation period on ice. Then, 0.2 ml of 10 N KOH was added and the samples were centrifuged at 12 000 g for 10 min at 4 1C. The nucleotide containing the supernatant fraction was then stored atÀ80 1C.
Ganciclovir analysis was performed at the Mayo Laboratories in Rochester, MN, USA. The method used high-pressure liquid chromatography. Results were reported as mg ml À1 and were converted to molar concentration.
Statistical analysis
Comparison between the means was analyzed by analysis of variance using the computer program StatView (Abacus Corporation, Calabasas, CA, USA). Statistical significance was assumed for a Po0.05 and is indicated by asterisks in the graphs.
Results
Toxicity
The treatment was extremely well tolerated without any serious side effects (Grade 3 or 4) being recorded. On some occasions, Grade 1 fever was measured that occurred within hours to days after injection and was believed to be treatment related. However, this was not PA1STK dose related. Mild tachycardia was also sometimes associated with cell infusions and observed in patients who developed fever. Grade 1 malaise and Grade 1 dyspnea was occasionally reported during the treatment period. No other side effects following intrathoracic injection of PA1STK cells were recorded (Table 3) .
Efficacy
No objective tumor responses were observed radiographically. Stable disease was documented in nine patients at 3 months and in three patients at 6 months following treatment initiation. Median overall survival was 7.7 months with survival ranging from 3 to 14 months (Table 4) .
Ganciclovir pharmacokinetics
The data reveal that therapeutic levels of GCV were reached in the pleural fluid following the initial dose of the treatment, and that therapeutic levels defined as trough levels were sustained throughout the course of the treatment program. Therapeutic levels are defined as the concentration that achieved complete kill of a panel of HSVtk-transfected cancer cell lines (2.0 mM). 21, 22 In order to establish an early pleural and serum GCV pharmacokinetics, we conducted a time course extraction study. The results presented in of Figure 1a show GCV levels over the first 6 h following the first infusion of GCV and are the cumulative data points of six patients. The data show that within 1 h after receiving GCV, the drug has entered in the pleural cavity at levels comparable to serum levels. Furthermore, tissue penetration into cells recovered from the pleural fluid was equal to serum and pleural fluid Figure 1b depicts the cumulative data for daily peak and trough levels of both serum and pleural fluid for all patients during their first treatment with PA1STK cells. The data demonstrate that distribution of GCV into the pleural fluid occurs rapidly with fast equilibration between serum and pleural fluid. The GCV concentration remains at or above the presumed threshold level of 2.0 mM throughout the course of the timed study.
Serum and pleural fluid GCV concentrations were also analyzed by cell dose. The dose of infused cells did not significantly influence pleural GCV concentration (data not shown).
PA1STK intrapleural infusion induces both localized as well as systemic immunity
Both pleural samples as well as peripheral blood samples were drawn 24 h post intrapleural cell infusion and were subsequently analyzed. Individual cytokines (Th1: interleukin (IL)-2, IL-12, IL15, IL-18 and granulocyte macrophage colony-stimulating factor and Th2: IL-4, IL-10, IL-13 and regulatory cytokines, transforming growth factor-b1 and IL-10) are expressed as fold-increase over baseline (pretreatment). Baseline specimens were obtained immediately before PA1STK infusion. Patients receiving repeat PA1STK infusions (cohorts 3-5) were analyzed sequentially for each treatment. Cumulative mean data are expressed for each treatment cohort (Figures 2a and b) .
The data does not demonstrate significant changes over initial versus repeat treatments. Moreover, the cytokine fold-increase in patients receiving low-dose PA1STK treatments versus higher dose treatments did not vary significantly (data not shown). Induction of Th1 cytokines paralleled the induction of Th2 cytokines in time course as well as in magnitude. The regulatory cytokines transforming growth factor-b1 and IL-10 were induced in both serum and pleura. Although induction of transforming growth factor-b1 was relatively small, IL-10 pleura levels increased by up to sevenfold, and were significantly higher than serum IL-10 levels, which increased to a maximum of threefold over the baseline (Figure 2c ).
Discussion
The study demonstrated that gene-modified cell-based intrathoracic therapy for compartmentalized tumors is feasible. Moreover, GCV, the essential prodrug for HSVtk-based suicide gene therapy achieves therapeutic doses in target tissues. We showed that GCV accumulates rapidly within 1 h of administration in the pleural fluid compartment with concentrations paralleling serum concentrations. Moreover, the therapeutic threshold Response rate CR (0), PR (0) and stable disease (9) and (3) at 3 and 6 months, respectively.
Abbreviations: CR, complete response; PR, partial response. Response rate and time to disease progression were assessed using the Worlds Health Organization criteria and calculated as median of all 15 patients. Grade I (6), Grade II (3) Cardiac arrhythmias (tachycardia) Grade I (4) Malaise Grade I (7) Dyspnea Grade I (4), Grade II (2) Toxicity was recorded using the NCI-CTC version 1.0 for all 15 patients. The number of events is in brackets next to the recorded grade.
Treatment of mesothelioma with gene-modified cells P Schwarzenberger et al concentration levels of 2.0 mM were exceeded within 1 h of first dose administration. Steady therapeutic trough GCV levels were achieved on day 2, which remained above the therapeutic threshold levels throughout the entire treatment course. Because at the time of trial initiation, no pharmacokinetic data for GCV of the pleural space existed, for safety reasons, PA1STK cells had to be preincubated in GCV for 2 h before infusion. This required preincubation step did not significantly affect pleural GCV levels as no statistically significant differences between high-and low-dose cell infusions were seen. The pharmacokinetic data support the rationale for further developing GCV-based suicide gene therapy studies for thoracic malignancies. The lung is often affected by systemic cytomegalovirus infections in immunocompromised patients. Although due to lack of alternatives GCV is administered under such circumstances regardless, despite lack of pharmacokinetic data. 23 The GCV pharmacokinetic data now provide a pharmacological rationale for this therapeutic strategy.
The treatment induced both systemic as well as intracavitary immune responses as the induction of Th1 cytokines up to 20-fold after PA1STK infusion over baseline suggests. This response did not seem to be dosedependent, and cytokine levels had normalized to baseline levels at the time of re-infusion 4 weeks later. Moreover, the immune responses observed during repeat administrations of HSVtk cells remained relatively constant. Th2 cytokines were also induced in response to intrathoracic PA1STK infusions, and the time course as well as the magnitude of the response paralleled that of the Th1 cytokines. Probably, the starting dose of PA1STK cells already sufficed in achieving the maximum immunemediated effect achievable, because neither Th1 nor Th2 cytokine profiles appeared to be dose-dependent.
In murine models, PA1STK cells were found to seek and adhere to intracavitary tumors. Using radioactively tagged PA1STK in patients valid for this preclinical model, we previously published that PA1STK cells in this human mesothelioma trial did also not simply float in the pleural effusion, but as similar to the animal model, adhered directly and accumulated around the tumors. When scintillation scans were overlayed with computed tomography scans, a perfect match with tumor contours was visualized. 24 These findings suggests that, in principle, the direct cytotoxic effect of this strategy as well as the bystander effect can also be accomplished in cancer patients. The induction of the cytokine cascades observed in humans are similar to profiles observed in preclinical studies supports this hypothesis. 9, 13, 17 Analogous to previously published animal models, this would suggest that the treatment induces an immunostimulatory tumor Treatment of mesothelioma with gene-modified cells P Schwarzenberger et al microenvironment, a condition found to be critical for in vivo efficacy of this therapeutic approach. 13 This antitumor effect was neither observed in immunocompromised animals nor in animals in which the cytokine cascade was experimentally abolished. 7 Given the design of a phase I study, the number of patients was small and there was also no control arm; therefore the information gained is limited. It would be conceivable to postulate that simply the infusion of allogeneic cells into the tumor microenvironment induced a cytokine response. However, as without GCV administration in preclinical studies, neither a cytokine response nor an anti-tumor response was observed, we believe that in humans the HSVtk-GCV effect is also the critical pathway that is required for the induction of cytokine response. Nevertheless, in contrast to our preclinical studies, we did not observe objective tumor responses using standard clinical response assessment criteria, such as radiographic studies. However, response assessment in mesothelioma is difficult and often unreliable. This is in part related to the fact that mesothelioma consists not only of viable tumor but also of matrix and fibrous tissue, which is less likely to respond to any form of biological or chemotherapy. Because of the small number of patients, it is not possible to accurately determine the efficacy. The median survival time in this study was within the range of expected survival time for that disease. Despite the lack of objective radiographic responses, immune-based cancer therapies may still provide a clinical benefit that is independent of such objective response. For instance, two recent phase III immunotherapeutic studies demonstrated substantial overall survival benefit, despite the lack of response rates or significantly improved progression free survival. 1, 2 Such a benefit could only be determined through a larger clinical trial. Given the concurrent induction of immunosuppressive Th2 cytokines or IL-10, which counteract immune-stimulating TH1 cytokines, one strategy to potentially improve on this therapeutic concept would be to combine PA1STK infusions with Th2 or IL-10 neutralizing antibodies or Th2 decoy constructs. Alternatively, this treatment could be combined with other immune-enhancing strategies, which are currently under development for mesothelioma. 15, 19, 25, 26 
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